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Background: Although the benefits of antipsychotic pharmacotherapy can be pronounced, many patients develop
unwanted adverse effects including a variety of movement disorders. Compared with the traditional antipsychotics, the
atypical antipsychotics have a decreased risk for associated movement disorders. Drug-induced movement disorders
can occur, however, and the risk of adverse events can increase significantly when medications are abused.
Case presentation: We describe the case of a 13-year-old male who presented to an emergency department with acute
movement disorders after nasal insufflation of crushed quetiapine. The patient was admitted and successfully treated for
neuroleptic toxicity with intravenous antihistamine pharmacotherapy. His primary care provider and psychiatrist were
notified of the abuse, quetiapine was discontinued, and the patient was discharged and referred to a drug and alcohol
awareness and abuse program.
Conclusions: The abuse of quetiapine has unfortunately become more common. This unique case report of acute
movement disorders following nasal insufflation of quetiapine highlights the need for heightened vigilance when
prescribing quetiapine and for increased awareness and education regarding medication-abuse.
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Quetiapine is an atypical antipsychotic, and its indications
include psychosis, mood disorders, and bipolar disorder. It
is intended for oral administration with total daily doses
up to 800 mg in adults. Quetiapine has good efficacy, but
also has some potential for abuse (see Table 1). Routes of
abuse include insufflation and intravenous entries.
Quetiapine has been associated infrequently with tardive
dyskinesia [9-11] and with acute movements disorders in-
cluding myoclonus [12-14], dystonia [15], parkinsonism
[16] and akathisia [17]. Drug-induced movement disorders
have also been associated with cases of abuse [18]; how-
ever, most subjects were either psychotic inpatients or in-
carcerated individuals. This case is unique in that it
involves an adolescent abusing quetiapine, via nasal insuf-
flation, in an out-patient setting.* Correspondence: Drmg456@gmail.com
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A 13-year old male presented to an ED with complaints of
“frequent eye blinking” and reoccurring episodes of “stiff-
ening and abnormal movements of the hands and neck”
and “flickering of the upper lips” that began 24 hours prior
to his arrival. About one week prior to presenting at the
ED, the patient had been discharged from a psychiatric
hospital, and his discharge medications for his mood dis-
order (Mood Disorder Not Otherwise Specified) included
quetiapine 500 milligrams (mg) by mouth (PO) daily (qd)
and valproic acid (VPA) 500 mg PO at bedtime (qhs). His
dosing regimen of quetiapine for the three months before
that hospitalization had been 100 mg qd, and he had not
previously been prescribed VPA.
The patient reported having insufflated two crushed tab-
lets of quetaipine 500 mg on four separate occasions in
the previous forty-eight hours. His desire to experience
euphoria motivated him to abuse his prescription quetia-
pine. He reported having not taken his prescribed VPA in
three days and also reported that he had not recently used
any other medications, supplements, or illicit drugs. HisLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Case report of quetiapine abuse
First author Year Patient demographics Description of quetiapine abuse Other relevant details
Fischer [1] 2010 53-year-old male Unknown amount, orally Alcohol abuse
Paparrigopoulos [2] 2008 48-year-old male 1000 mg/day orally Alcohol/benzodiazepine dependence
Murphy [3] 2008 29-year-old male Unknown amount, orally Feigned psychotic symptoms
Reeves [4] 2007 49-year-old male 800 mg/day orally Alcohol/benzodiazepine abuse
23-year-old male 2400 mg/day, orally Benzodiazepine dependence
39-year-old male 800 mg/day, orally Exaggerated bipolar symptoms
Pinta [5] 2007 39-year-old male 600 mg/day, orally Opiate abuse; demanded treatment with quetiapine
Morin [6] 2007 28-year-old female Unknown amount, insufflation Polysubstance abuse
Waters [7] 2007 33-year-old male 400-800 mg, intravenously Polysubstance dependence including benzodiazepines
Hussain [8] 2005 34-year-old female 600 mg, intravenously Polysubstance abuse, borderline personality disorder
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quetiapine, the episodes of excessive eye-blinking and lip-
flickering were intermittent, and the twitching of his eye-
lids was continuous.
At the time of presentation, the patient was fully alert
and had a Glascow Coma Scale of 15. He was afebrile,
tachycardic (115 beats/minute), tachypnic (18 respira-
tions/minute), and had normal oxygen saturation with-
out supplemental oxygen. Physical exam abnormalities
included only active twitching of both upper eyelids and
bilateral dilated pupils (4/5). During observation in the
emergency department, the patient had two myoclonic
episodes of the extremities and intense flickering of the
eyelids that the patient reported were associated with
him turning his head to the right. The episodes lasted
about two minutes, and the patient was alert and ori-
ented during the episodes. The patient reported feeling
restless and had a constant desire to walk. Results from
a 10-panel urine toxicology screen performed at admis-
sion were negative for common drugs of abuse, and lor-
azepam 1.5 mg intravenous (IV) was given to relax the
patient. His restlessness worsened, however, and he was
admitted for observation and treatment of neuroleptic
toxicity. Diphenhydramine 50 mg IV was administered,
and he was in stable condition within 24 hours. Quetia-
pine was discontinued, and the patient was discharged
and referred for substance abuse evaluation and treat-
ment. His primary care provider and psychiatrist were
notified regarding the medication abuse.
Conclusions
We report a case of acute movement disorders in an
adolescent that likely resulted from quetiapine abuse
(nasal insufflation of crushed tablets). Many patients em-
bellish or malinger to obtain quetiapine, and its abuse is
not uncommon [8,19]. Quetiapine tablets can be crushed
into powder, and many abusers will either insufflate the
powder or will solubilize the powder and inject it intra-
venously. Abusers choose these routes of administrationin order to experience more rapid onset of quetiapine’s
anxiolytic effects. The toxicokinetics of intranasal insuf-
flation of quetiapine have not been fully characterized,
but this route of administration undoubtedly leads to
significant acute levels of quetiapine in the central ner-
vous system. This sudden substantial exposure is likely
responsible for the acute episodes of dyskinesia, myoclo-
nus and akathisa described in this case. The movement
disorders described in this case were not likely related to
use of VPA because their associations with VPA are ex-
tremely rare [20] and the patient had not been exposed
to VPA (half-life 9–16 hours) in several days.
Exposure to other drugs of abuse (e.g., cocaine, phen-
cyclidine) can cause acute movement disorders; however,
the urine toxicology results and the patient report do
not suggest that other drugs of abuse were involved in
this case report.
Per Hill’s Criteria of Causation [21], one can reasonably
conclude that this patient’s dyskinesia was related to que-
tiapine exposure. According to Narnajo’s Adverse Drug
Reaction (ADR) scale [22] for this case, the score was 6,
indicating probable cause (> 9 = definite ADR, 5–8 = prob-
able ADR, 1–4 = possible ADR 0 = doubtful ADR). The
quick response to anticholinergic pharmacotherapy is also
suggestive of acute neuroleptic-associated dyskinesia. Lim-
itations of our report include a lack of serum quetiapine
measurements. This report, however, highlights the need
for increased prescribing vigilance and abuse-potential
awareness.
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